Pipeline — registered trials by phase
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
— · Hypoparathyroidism · Recruiting · est. 2027-08
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
— · Growth Hormone Deficiency · Recruiting · est. 2033-03
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
— · Growth Hormone Deficiency · Recruiting · est. 2033-03
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
— · Hypoparathyroidism · Recruiting · est. 2036-01
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
— · Achondroplasia · Completed · est. 2024-01-12
Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)
— · Healthy · Completed · est. 2010-02
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
— · Achondroplasia · Recruiting · est. 2027-12
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
— · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases · Completed · est. 2020-03-06
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
— · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor · Active Not Recruiting · est. 2027-08
A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency
— · Adult Growth Hormone Deficiency · Completed · est. 2011-05
A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia
— · Achondroplasia · Active Not Recruiting · est. 2025-11-14
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
— · Growth Hormone Deficiency (GHD) · Completed · est. 2015-07
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
— · Turner Syndrome · Active Not Recruiting · est. 2024-10-18
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
— · Achondroplasia · Recruiting · est. 2027-08
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
— · Achondroplasia · Completed · est. 2022-09-27
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
— · Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases · Completed · est. 2019-01-17
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
— · Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency · Completed · est. 2019-03-19
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
— · Hypoparathyroidism · Recruiting · est. 2027-08
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
— · Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature · Recruiting · est. 2028-02
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
— · Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency · Completed · est. 2023-02-21
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
— · Achondroplasia · Enrolling By Invitation · est. 2039-01
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
— · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases · Recruiting · est. 2027-06
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism
— · Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases · Completed · est. 2022-01-12
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
— · Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency · Completed · est. 2024-12-23
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
— · Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency · Completed · est. 2023-11-02
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
— · Achondroplasia · Completed · est. 2024-08-09
YuviwelNavepegritide
Source: ClinicalTrials.gov (trials where Ascendis is lead sponsor; 26 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 6-K2026-09-29Report of foreign issuer
- 6-K2026-09-15Report of foreign issuer
- 6-K2026-09-15Report of foreign issuer
- 6-K2026-09-09Report of foreign issuer
- 6-K2026-09-09Report of foreign issuer
- 6-K2026-08-31Report of foreign issuer
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- 6-K2026-08-13Report of foreign issuer
- 6-K2026-08-13Report of foreign issuer
- 6-K2026-08-12Report of foreign issuer
- 6-K2026-08-06Report of foreign issuer
- 6-K2026-07-15Report of foreign issuer
- 6-K2026-06-30Report of foreign issuer
- 6-K2026-06-29Report of foreign issuer
- 6-K2026-06-17Report of foreign issuer
- 6-K2026-06-15Report of foreign issuer
- 6-K2026-06-12Report of foreign issuer
- 6-K2026-06-10Report of foreign issuer
- SD2026-05-22SD
- SCHEDULE 13G/A2026-05-15SCHEDULE 13G/A
- SCHEDULE 13G/A2026-05-14SCHEDULE 13G/A
- 6-K2026-05-13Report of foreign issuer
- SCHEDULE 13G/A2026-05-07SCHEDULE 13G/A
- SCHEDULE 13G2026-05-07SCHEDULE 13G
- 6-K2026-05-07Report of foreign issuer
- 6-K2026-05-07Report of foreign issuer
- SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
- 6-K2026-04-21Report of foreign issuer
- 6-K2026-04-21Report of foreign issuer
- 8-A12B/A2026-04-208-A12B/A
- 6-K2026-04-20Report of foreign issuer
- 6-K2026-04-16Report of foreign issuer
- 6-K2026-04-08Report of foreign issuer
- 6-K2026-04-08Report of foreign issuer
- 6-K2026-04-07Report of foreign issuer
- 6-K2026-03-30Report of foreign issuer
- 6-K2026-03-24Report of foreign issuer
- 6-K2026-03-17Report of foreign issuer
- 6-K2026-03-16Report of foreign issuer
- 6-K2026-03-11Report of foreign issuer
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.